Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

, which the company plans to develop into orally administered drugs for major depression and other psychiatric disorders.

NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in- vitro. In mice, NSI-189 stimulated neurogenesis in the hippocampus and increased its volume. In humans, NSI-189 may reverse the human hippocampal atrophy seen in major depression and other disorders. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is conducting an ongoing FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  Neuralstem's first small molecule compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depr
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 Today AmerisourceBergen, ... three new distribution centers in Olive Branch, ... and Newburgh, NY . The facilities ... ability to improve product access, increase supply chain efficiency ... is part of the company,s ongoing investments, more than ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 ... the addition of the "Electrophysiology Market by ... (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, Generator, ... Global Forecasts to 2019" report to their ... is estimated to grow at a significant CAGR ...
(Date:6/2/2015)... , June 2, 2015  Australian health technology ... AUD$14.8 million to rapidly progress the company,s ... KinetiGraph™ (PKG™) mobile health technology. ... further capital in the funding round. New ... high net worth individuals and also the ...
Breaking Medicine Technology:AmerisourceBergen to Build Three New Distribution Centers 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 3Global Kinetics Corporation Closes AUD$14.8 Million Capital Raising 2Global Kinetics Corporation Closes AUD$14.8 Million Capital Raising 3
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... webcast on Friday, September 17, 2010, at 7:00 a.m. ... Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs ... on September 16, 2010, to review the lorcaserin New ...
... Switzerland, and BANGALORE, India, Sept. 13 Debiopharm ... companies with a focus on the development of ... and Aurigene Discovery Technologies Ltd. (Aurigene), a Bangalore-based ... and peptide drug discovery and development from target ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting 2Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting 3Debiopharm Group™ and Aurigene Nominate Development Candidate 2Debiopharm Group™ and Aurigene Nominate Development Candidate 3
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 ... has joined the firm in a newly created position ... accounts and support organizations committed to improving employee retention ... a wealth of marketing experience and most recently worked ... up that was recently taken over a global mobile ...
(Date:6/2/2015)... Camarillo, Calif. (PRWEB) June 02, 2015 ... designing and manufacturing high performance connector solutions and ... MINI-SNAP® advanced connector solutions to the US market. ... connector with Push-Pull locking capabilities. The self- securing ... range of demanding applications that require significant customization ...
(Date:6/2/2015)... Residents of Monarch Landing in Naperville ... a fitness class, do yoga, play volleyball, or participate ... for the Alzheimer’s Association’s Walk to End Alzheimer’s on ... part in a challenge to exercise for 60 days, ... company. , While the walk will raise awareness of ...
(Date:6/2/2015)... The Radiosurgery Society® (RSS), a ... RSSearch® Patient Registry evaluating the treatment patterns and ... the treatment of centrally located primary non-small cell ... The study, published in the May, 2015, issue ... patients with 114 centrally located lung tumors who ...
(Date:6/2/2015)... Colleen’s Dream Foundation , with fundraising ... the UNMC to support ovarian cancer research conducted by Cheng ... of the Colleen’s Dream Foundation Board of Directors. , Cundiff ... date for Colleen’s Dream Foundation and they couldn’t have picked ... Wang is a rising star in the ovarian cancer world,” ...
Breaking Medicine News(10 mins):Health News:Insightlink Communications Appoints New Director of Marketing and Client Engagement 2Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... the research bolsters the idea that humans suffering from ... help preserve function by adding antioxidants to their diet, ... devised a new cell-based gene therapy technique that could ... these diseases. , The work, led by Scripps ...
... Corporation (Nasdaq: MASI ), the inventor of ... today announced that its management is scheduled to present ... Stock Conference at The Ritz-Carlton, Laguna Niguel in Dana ... a.m. PT. A live audiocast of the presentation will ...
... SOBeFiT Magazine, the first South Florida,publication dedicated to providing ... sports for men and women, will host its sold-out, ... presented by The Sports,Club/LA, as part of the series ... On February 8th, 2009, hundreds of ...
... not immediately order routine scans for low-back pain unless ... in the Oregon Evidence-Based Practice Center at Oregon Health ... this week,s edition of the The Lancet . ... scans in patients with low-back pain but no indication ...
... Corporation,(Nasdaq: VOLC ), a leader in the ... treatment of coronary and peripheral artery,disease, today announced that ... and all of fiscal 2008 on Tuesday, February 17. ... a conference call to discuss its financial results,and operating ...
... of its top priorities--reforming the nation,s health care system--twelve pharmacy stakeholder ... Reform, which will be announced during a media briefing on February ... ... Washington, DC (Vocus) February 6, 2009 -- As the new administration ...
Cached Medicine News:Health News:Team led by Scripps Scientists increases understanding of two types of blindness 2Health News:Team led by Scripps Scientists increases understanding of two types of blindness 3Health News:Team led by Scripps Scientists increases understanding of two types of blindness 4Health News:Team led by Scripps Scientists increases understanding of two types of blindness 5Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 2Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 3Health News:Routine scans for low-back pain do not improve outcomes 2Health News:Routine scans for low-back pain do not improve outcomes 3Health News:Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2Health News:Pharmacy Stakeholder Groups Collaborate to Draft Pharmacy Principles for Health Care Reform 2Health News:Pharmacy Stakeholder Groups Collaborate to Draft Pharmacy Principles for Health Care Reform 3
Small golf club shape tip with sharp edge. Flat serrated handle with polished finish. Most popular size or model....
Threaded ends permit guarding the needle and gouge within the handle. Set consists of one each : E0828 A needle tip, E0828 B gauge tip and E0828 C handle. Most popular size or model....
0.5 mm replacement burr for Algerbrush rust ring remover (E0815 A). Burr can also be used with Algerbrush rust ring remover (E0815 B). Dull finish....
Short 12 mm taper with needle type tip. Stainless steel. Round smooth handle with polished finish. Overall length: 2.8 inches....
Medicine Products: